11-16-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com

Stephen Bernard, AP Business Writer

Stocks retreat on Asian inflation, Euro debt fears

Stocks fall amid worries about rate hikes in Asia, possible bailouts in Europe

NEW YORK (AP) — Stocks retreated Tuesday following new worries about rising inflation in Asia and the possibility Ireland might need a bailout.

The Dow Jones industrial average fell 73 points in morning trading. The losses piled up even as shares of two components of the index, Home Depot Inc. and Wal-Mart Stores Inc., rose more than 2 percent following improved earnings.

Asian markets fell overnight after South Korea's central bank raised interest rates to curb growing inflation. There has been speculation in recent days that China will have to take similar steps soon.

A report in the U.S. showed inflation at the wholesale level was smaller than predicted. The producer price index rose 0.4 percent last month, half of what economists' expected. The rise was due to a sharp increase in food and energy costs. Stripping out those volatile costs, prices fell 0.6 percent. The report backs up the Federal Reserve's view that inflation remains low because of sluggish growth.

Yesterday's Top Performing Small Cap Stock:

Suffer (Pink Sheets: ENTK)

Suffer was a SmallCapVoice.com top performer closing up over 7% on trading volume of 120,000 shares.

SUFFER is an apparel design and manufacturer company. SUFFER specializes in the production of high end clothing for men and is in design phase for women.

SUFFER is starting out by catering to the MMA (Mixed Martial Arts) as this is the fastest growing sport/fanbase in the world. Suffer believes it has an edge in having one of the top 5 MMA athletes serving as a Director of the company.

Currently most sales are done online through its website, the company is however starting to expand its wholesale division to allow other websites and physical storefronts to sell its apparel.

Today's SmallCapVoice.com Hot Stock to Watch:

Tootie Pie Company TOOT

Tootie Pie Company, Inc. TOOT announced that sales jumped 32% to $315,907 for the quarter ended September 30, 2010 versus $239,691 for the same period in 2009.

Other Small Cap News

Biomoda, Inc. BMOD

Biomoda Selects Quintiles to Help Develop More Accurate Automated System for Detecting Early-Stage Lung Cancer

Quintiles' expertise tapped to refine Biomoda's digital cytopathology system

ALBUQUERQUE, N.M. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Cancer diagnostics company Biomoda, Inc. (OTC BB:BMOD) (www.biomoda.com) has allied with Quintiles Global Central Laboratories (www.quintiles.com) to help refine the automated image recognition system for measuring the photon emission rate and cell morphology of CyPath®-stained cells to detect early stage lung cancer.

Lucas Energy, Inc. (NYSR Amex: LEI)

Lucas Energy Announces New Joint Venture Partner in Its Wilson County, Texas Eagle Ford Properties

HOUSTON, Nov. 15, 2010 (GLOBE NEWSWIRE) — Lucas Energy, Inc. (NYSE Amex:LEI), an independent oil and gas company (the “Company” or “Lucas”), today announced that Hall Phoenix Energy LLC has acquired the deep rights (Eagle Ford formation and below) in acreage operated by Lucas in Wilson County, Texas. Hall Phoenix Energy, Inc. acquired various working interests (from 50% up to 80%) from a third party joint venture partner of Lucas. The seller sought to raise cash and reduce its capital exposure for the future.

Cytori Therapeutics, Inc. CYTX

Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients; Statistically Significant Improvement in MVO2 Reported by Cytori at American Heart Association

SAN DIEGO, CA–(Marketwire – 11/15/10) – Adipose (fat) tissue-derived regenerative cells (ADRCs) obtained using the Celution® System demonstrated a statistically significant improvement in cardiac functional capacity (MVO2) at 18 months in Cytori's CYTX PRECISE trial for chronic myocardial ischemia. New data from this trial were presented today at the American Heart Association Scientific Sessions 2010 in Chicago by Co-Principal Investigator Emerson C. Perin, MD, PhD, Director, Clinical Research for Cardiovascular Medicine, and Medical Director, Stem Cell Center, Texas Heart Institute.

Apricus Biosciences, Inc. APRI

Apricus Biosciences Receives Canadian Approval for Vitaros® as First Line Therapy for Erectile Dysfunction

SAN DIEGO–(BUSINESS WIRE)– Apricus Biosciences, Inc. (“Apricus Bio”) APRI, announced today that Health Canada has granted marketing approval for Vitaros® as a first-line therapy for erectile dysfunction. Vitaros® is Apricus Bio's proprietary, topically-applied, on-demand treatment for erectile dysfunction.

Cogo Group, Inc. COGO

Cogo Announces Design Wins With Chery, China's Largest Domestic Auto Vendor

China October Passenger Vehicle Sales up 27% Year over Yea

SHENZHEN, China, Nov. 16, 2010 /PRNewswire/ — Cogo Group, Inc. COGO, a leading embedded solutions and software provider for the technology and industrial sectors in China, today announced a series of design wins with Chery, China's largest domestic automobile vendor. Cogo, in conjunction with its partner, a leading global semiconductor supplier for the auto industry, will provide highly technical module and software solutions for a variety of applications, including Anti-Lock Braking Systems (“ABS”) and Adaptive Front-Lighting System (“AFS”).

PolyMedix, Inc. PYMX

PolyMedix and University of Massachusetts Receive $750,000 Contract from U.S. Army Research Office

Supports Continued Development of Novel Antibacterial Compounds Against Drug Resistant Bacterial Biofilms

RADNOR, Pa.–(BUSINESS WIRE)– PolyMedix, Inc. PYMX, an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, Amherst (UMass), have received a Phase 2 Small Business Technology Transfer (STTR) contract in the amount of $750,000. This contract will allow PolyMedix to conduct further testing on antimicrobial compounds which PolyMedix identified under the initial Phase 1 contract. These compounds are being developed to specifically treat multi-drug resistant biofilm-embedded bacteria. This award represents the 15th grant or research contract received to date by PolyMedix.

Progenics Pharmaceuticals, Inc. PGNX

Progenics Pharmaceuticals Announces Phase 2 Clinical Trial of Subcutaneous Methylnaltrexone in Japan by Ono Pharmaceutical

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Progenics Pharmaceuticals, Inc. PGNX today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. (OSE-TYO: 4528). The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer. Subcutaneous methylnaltrexone is already marketed in the U.S. and in certain ex-U.S. markets under the brand name RELISTOR®.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide. Known for its ability to help emerging growth companies build a following among retail and institutional investors, SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well small cap company's financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.

The SmallCapVoice.com, Inc. Daily Highlights is an electronic publication, and is for informational purposes only. The Small Cap Voice Daily Highlights covers both client and non client issuers. Non client issuer's news is listed under other small cap news. SmallCapVoice is an electronic publication providing information on selected public companies. All companies profiled on this website pay cash or restricted stock to SmallCapVoice as consideration for the electronic dissemination of the company's information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that SmallCapVoice fully disclose the type consideration (i.e. cash, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. SmallCapVoice is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. The information contained in our website, e-mail communications and publications are carefully compiled by SmallCapVoice from public sources that we believe to be reliable. SmallCapVoice, however, does not guarantee the accuracy of any information contained in our website, e-mail communications or publications. This material is not a substitute for either one's own thorough investigation of an investment opportunity or the exercise of good business judgment. SmallCapVoice does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data obtained from third party sources that are published by us about the profiled companies in our website articles, e-mail communications or publications, but we do not publish information that we know is incorrect. Investors should not rely solely on the information contained in our website, e-mail communications or publications when making investment decisions. Instead, investors should use the information provided on the profiled companies as a starting point for conducting additional research that will permit them to form their own opinions regarding the appropriateness of an investment in the profiled company's securities. SmallCapVoice does not warrant, represent or guaranty that there has been no change in the affairs of the profiled company since the date that information was published on this website, in e-mail communications or in our publications regarding a profiled company or after the date of the profiled company's press releases or other information disseminated via our website or publications. If you become aware of any change of circumstances related to any website article, e-mail communication or publication, please notify us immediately. See the Contact Us page for the appropriate e-mail address. The information contained in our website, e-mail communications and publications pertains to microcap, small cap and/or other thinly traded securities which by their very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all of an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find encounter difficulties in liquidating the securities. SmallCapVoice may liquidate the stock consideration it receives at any time it deems it appropriate to do so after the required six-month holding period has run after the completion of the services for which SmallCapVoice was paid in stock. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company's securities. The following companies have paid, and/or have agreed to pay SmallCapVoice to: distribute the company's information and reports on this website, to send e-mail communications; to send publications by mail, to post company Internet links on our website, and to compile and/or to distribute reports in an e-mail newsletter.

We encourage our readers to use caution when investing and educate themselves at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at www.nasd.com. We encourage you to study the SEC's policies regarding online newsletters at http://www.sec.gov/answers/newsltr.htm. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our site.

Contact:

Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com